We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MEDNAX's Ratings Get Affirmed by Moody's, Outlook Negative
Read MoreHide Full Article
Credit rating giant Moody’s Investors Service affirmed MEDNAX, Inc.'s (MD - Free Report) Ba2 Corporate Family Rating, the Ba2-PD Probability of Default Rating and the Ba2 rating on its unsecured bonds due in 2023 and 2027. However, the outlook was altered to negative from stable.
Ratings Representation
This revised negative outlook reflects MEDNAX’s eroding profit margins due to high compensation costs, mainly in its anesthesia business. In the last couple of years, the company’s debt/EBITDA increased by around a turn to 3.6 times (as of Sep 30, 2109). This new outlook also emphasizes the unpredictability regarding the company’s return to earnings growth via its current restructuring initiatives.
Meanwhile, the affirmation of the ratings underlines the company’s high free cash flow. The credit rating agency expects MEDNAX to generate more than $250 million of free cash flow. This apart, it also confirms that the company is well-equipped with balanced financial policies.
Factors Driving the Ratings
The company’s Ba2 Corporate Family Rating acknowledges its solid status in neonatology and anesthesiology, exposure to the changing regulatory landscape revolving around reimbursements and its moderate leverage. The rating authority also anticipates the company’s leverage with debt/EBITDA to stay above 3.5x for 2020.
However, the credit rating giant expects the leverage to improve as MEDNAX works on its margins over time through restructuring plans. The company’s rating is further cushioned by customer diversity, healthcare services that are outsourcing market trends, liquidity level and buyouts.
The company's Speculative Grade Liquidity -1 Rating supports Moody’s expectation for MEDNAX to maintain solid liquidity over the next year. An upgrade is not likely to take place over the upcoming 12-18 months.
Factors That can Change the Outlook
The ratings can see a constant upgrade over a considerable period of time provided the company can manage its buyout strategies and execute its cost-saving plans. Ratings could be enhanced if debt/EBITDA is retained below 2.5 times.
Also, the ratings can see a downgrade if the company is unable to improve its operating performance and quantitatively, ratings could again decline if debt/EBITDA is sustained above 3.5 times.
Shares of this Zacks Rank #3 (Hold) company have lost 34.5% in a year’s time against its industry’s growth of 4.1%.
Downward Estimate Revision
The stock has witnessed a downward revision in 2019 and 2020. Earnings estimates have moved 0.9% and 2% south, respectively, over the past seven days. With the recent revision of rating outlook to negative, the stock might further trigger a downward revision in earnings estimates.
HCA Healthcare provides health care services. In the trailing four quarters, the company came up with average beat of 9.3%. It carries a Zacks Rank #2 (Buy).
Tenet Healthcare works as a diversified healthcare services company. In the last four quarters, the company delivered average beat of 81.7%. The stock has a Zacks Rank of 2.
WellCare Health provides government-sponsored managed care services. In the last four quarters, the company pulled off average beat of 17.3%. It sports a Zacks Rank #1 (Strong Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
MEDNAX's Ratings Get Affirmed by Moody's, Outlook Negative
Credit rating giant Moody’s Investors Service affirmed MEDNAX, Inc.'s (MD - Free Report) Ba2 Corporate Family Rating, the Ba2-PD Probability of Default Rating and the Ba2 rating on its unsecured bonds due in 2023 and 2027. However, the outlook was altered to negative from stable.
Ratings Representation
This revised negative outlook reflects MEDNAX’s eroding profit margins due to high compensation costs, mainly in its anesthesia business. In the last couple of years, the company’s debt/EBITDA increased by around a turn to 3.6 times (as of Sep 30, 2109). This new outlook also emphasizes the unpredictability regarding the company’s return to earnings growth via its current restructuring initiatives.
Meanwhile, the affirmation of the ratings underlines the company’s high free cash flow. The credit rating agency expects MEDNAX to generate more than $250 million of free cash flow. This apart, it also confirms that the company is well-equipped with balanced financial policies.
Factors Driving the Ratings
The company’s Ba2 Corporate Family Rating acknowledges its solid status in neonatology and anesthesiology, exposure to the changing regulatory landscape revolving around reimbursements and its moderate leverage. The rating authority also anticipates the company’s leverage with debt/EBITDA to stay above 3.5x for 2020.
However, the credit rating giant expects the leverage to improve as MEDNAX works on its margins over time through restructuring plans. The company’s rating is further cushioned by customer diversity, healthcare services that are outsourcing market trends, liquidity level and buyouts.
The company's Speculative Grade Liquidity -1 Rating supports Moody’s expectation for MEDNAX to maintain solid liquidity over the next year. An upgrade is not likely to take place over the upcoming 12-18 months.
Factors That can Change the Outlook
The ratings can see a constant upgrade over a considerable period of time provided the company can manage its buyout strategies and execute its cost-saving plans. Ratings could be enhanced if debt/EBITDA is retained below 2.5 times.
Also, the ratings can see a downgrade if the company is unable to improve its operating performance and quantitatively, ratings could again decline if debt/EBITDA is sustained above 3.5 times.
Shares of this Zacks Rank #3 (Hold) company have lost 34.5% in a year’s time against its industry’s growth of 4.1%.
Downward Estimate Revision
The stock has witnessed a downward revision in 2019 and 2020. Earnings estimates have moved 0.9% and 2% south, respectively, over the past seven days. With the recent revision of rating outlook to negative, the stock might further trigger a downward revision in earnings estimates.
Stocks to Consider
Investors interested in the medical sector can take a look at some better-ranked stocks like HCA Healthcare, Inc. (HCA - Free Report) , Tenet Healthcare Corporation (THC - Free Report) and WellCare Health Plans, Inc. . You can see the complete list of today’s Zacks #1 Rank stocks here.
HCA Healthcare provides health care services. In the trailing four quarters, the company came up with average beat of 9.3%. It carries a Zacks Rank #2 (Buy).
Tenet Healthcare works as a diversified healthcare services company. In the last four quarters, the company delivered average beat of 81.7%. The stock has a Zacks Rank of 2.
WellCare Health provides government-sponsored managed care services. In the last four quarters, the company pulled off average beat of 17.3%. It sports a Zacks Rank #1 (Strong Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>